Eris Lifesciences Stock Screener | Share Price & Fundamental Analysis
ERIS
Pharmaceuticals
Share Price NSE
₹1315.40
▼
-13.90 (-1.05%)
Share Price BSE
₹1317.30
▼
-10.75 (-0.81%)
Track Eris Lifesciences share price live with TickJournal's free stock screener.
Analyze Eris Lifesciences share price history trends and compare 52-week high low
levels.
Record your trades in TickJournal's free trading journal and track your portfolio performance.
Eris Lifesciences Market Cap
₹18,455.30 Cr.
ERIS P/E Ratio (TTM)
38.60
Eris Lifesciences P/B Ratio
5.17
EPS (TTM)
₹25.85
Dividend Yield
0.55%
Debt to Equity
0.97
ERIS 52 Week High
₹1847.70
Eris Lifesciences 52 Week Low
₹1271.00
Operating Margin
36.00%
Profit Margin
14.35%
ERIS Revenue (TTM)
₹711.00
EBITDA
₹258.00
Net Income
₹102.00
Total Assets
₹7,033.00
Total Equity
₹3,272.00
Eris Lifesciences Share Price History - Stock Screener Chart
Screen ERIS historical share price movements with interactive charts. Analyze price trends and patterns.
Eris Lifesciences Company Profile - Fundamental Screener
Screen Eris Lifesciences company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics
for ERIS shares.
Eris Lifesciences Limited is an Indian company that manufactures and markets pharmaceutical products. Founded in 2007, the company operates a manufacturing plant in Guwahati, Assam. Eris focuses on chronic, sub-chronic, and acute therapeutic areas, including cardiovascular, anti-diabetics, vitamins, gastroenterology, and anti-infective. The company has a portfolio of 112 Mother Brands...more
Sector
Healthcare
Industry
Pharmaceuticals
Sub-Sector
Pharmaceuticals
Segment
E
Chairperson/CEO
Amit Indubhushan Bakshi
ISIN
INE406M01024
Website
https://www.eris.co.in
Eris Lifesciences Balance Sheet Screener
Screen ERIS balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation
metrics.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||
| Total Assets | 7,033 | 7,041 | 3,667 | 2,272 | 1,835 | 1,552 | 1,554 | 1,460 | 727 | 398 |
| Current Assets | 1,223 | 2,302 | 765 | 627 | 467 | 480 | 582 | 299 | 216 | 237 |
| Fixed Assets | 5,307 | 4,319 | 2,568 | 918 | 854 | 875 | 761 | 771 | 232 | 65 |
| Liabilities | ||||||||||
| Total Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Liabilities | 2,380 | 1,286 | 1,003 | 164 | 91 | 91 | 79 | 349 | 60 | 25 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Shareholders' Equity | ||||||||||
| Total Equity | 3,272 | 3,222 | 2,221 | 1,908 | 1,576 | 1,296 | 1,169 | 886 | 591 | 302 |
| Share Capital | 14 | 14 | 14 | 14 | 14 | 14 | 14 | 14 | 14 | 0 |
| Reserves & Surplus | 2,841 | 2,573 | 2,182 | 1,894 | 1,563 | 1,283 | 1,137 | 848 | 553 | 302 |
Eris Lifesciences Income Statement Screener - Profit & Revenue Analysis
Screen Eris Lifesciences income statement and profit fundamentals.
Analyze ERIS quarterly results,
revenue growth, EBITDA, net profit margins, and EPS using TickJournal's fundamental screener for Eris Lifesciences share price evaluation.
| Item | 2025-Mar | 2025-Jun | 2025-Sept | 2025-Dec | 2024-Mar | 2024-Jun | 2024-Sept | 2024-Dec | 2023-Mar | 2023-Jun | 2023-Sept | 2023-Dec | 2022-Mar | 2022-Jun | 2022-Sept |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 711 | 775 | 793 | 801 | 562 | 717 | 744 | 726 | 398 | 461 | 504 | 488 | 309 | 395 | 461 |
| Expenses | 453 | 496 | 504 | 543 | 403 | 470 | 477 | 477 | 284 | 297 | 324 | 311 | 209 | 269 | 309 |
| EBITDA | 258 | 279 | 289 | 258 | 160 | 248 | 267 | 249 | 114 | 164 | 180 | 177 | 100 | 125 | 151 |
| Operating Profit % | 36.00% | 36.00% | 36.00% | 32.00% | 26.00% | 34.00% | 35.00% | 34.00% | 28.00% | 35.00% | 35.00% | 36.00% | 31.00% | 31.00% | 32.00% |
| Depreciation | 77 | 71 | 69 | 70 | 54 | 76 | 81 | 81 | 35 | 41 | 42 | 46 | 18 | 23 | 29 |
| Interest | 54 | 49 | 50 | 49 | 33 | 60 | 60 | 57 | 9 | 17 | 16 | 18 | 1 | 7 | 7 |
| Profit Before Tax | 129 | 161 | 173 | 145 | 77 | 116 | 129 | 116 | 76 | 113 | 126 | 116 | 85 | 101 | 121 |
| Tax | 27 | 36 | 38 | 37 | -3 | 26 | 33 | 29 | 14 | 19 | 4 | 14 | 5 | 8 | 2 |
| Net Profit | 102 | 125 | 135 | 109 | 80 | 90 | 96 | 87 | 62 | 94 | 122 | 102 | 80 | 93 | 119 |
| EPS | 6.90 | 8.66 | 8.82 | 7.32 | 5.22 | 6.11 | 6.73 | 6.16 | 4.81 | 6.97 | 9.08 | 7.55 | 5.91 | 6.96 | 8.84 |
Eris Lifesciences Cash Flow Screener - Liquidity Fundamentals
Screen ERIS cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price
strength assessment.
| Item | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March | 2016-March |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | 1,065 | 486 | 292 | 378 | 375 | 271 | 223 | 235 | 200 | 132 |
| Investing Activities | -78 | -1,828 | -975 | -320 | -323 | 123 | -5 | -590 | -185 | -44 |
| Financing Activities | -881 | 1,380 | 688 | -45 | -82 | -335 | -221 | 363 | -24 | -84 |
| Net Cash Flow | 106 | 38 | 5 | 14 | -30 | 60 | -3 | 8 | -8 | 4 |
Eris Lifesciences Shareholding Pattern Screener
See Eris Lifesciences shareholding pattern with promoter, FII, and DII holdings.
Check Eris Lifesciences promoter holding and ownership changes for ERIS on TickJournal.
| Item | 2025-Mar | 2025-Jun | 2025-Sept | 2025-Dec | 2024-Mar | 2024-Jun | 2024-Sept | 2024-Dec |
|---|---|---|---|---|---|---|---|---|
| Promoter Holding | 54.85% | 54.83% | 54.85% | 54.85% | 54.90% | 54.88% | 54.87% | 54.86% |
| FII Holding | 8.43% | 8.40% | 7.21% | 6.85% | 14.27% | 14.59% | 8.01% | 8.35% |
| DII Holding | 18.07% | 18.17% | 19.36% | 20.32% | 15.63% | 16.23% | 18.64% | 18.06% |
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 9.16% | 9.12% | 9.12% | 8.51% | 14.24% | 13.53% | 10.51% | 9.29% |
| Other Holding | 9.49% | 9.47% | 9.45% | 9.48% | 0.95% | 0.77% | 7.96% | 9.43% |
| Shareholder Count | 50,087 | 52,225 | 59,438 | 54,713 | 51,753 | 44,176 | 46,346 | 53,314 |
Eris Lifesciences Share Dividend Screener - Share Yield Analysis
Check Eris Lifesciences dividend history with payout and yield data.
View Eris Lifesciences dividend details including ex-dates and amounts for ERIS stock.
| Period | Dividend Per Share | Dividend Yield |
|---|---|---|
| 2026-March | ₹0.00 | 0.00% |
| 2025-March | ₹7.35 | 0.57% |
| 2024-March | ₹0.00 | 0.00% |
| 2023-March | ₹7.35 | 0.87% |
| 2022-March | ₹6.01 | 1.05% |
| 2021-March | ₹5.50 | 0.80% |
| 2020-March | ₹2.87 | 0.47% |
| 2019-March | ₹0.00 | 0.00% |
| 2018-March | ₹0.00 | 0.00% |
| 2017-March | ₹0.00 | 0.00% |
Eris Lifesciences Stock Index Membership
See which indices include Eris Lifesciences stock.
Check ERIS index membership in NIFTY 50, SENSEX, and other indices on TickJournal.
BSE 1000
BSE INDEX BSE HC
BSE INDEX BSE500
BSE INDEX MSL400
BSE INDEX SML250
BSE INDEX SMLCAP
NIFTY 500
NIFTY MIDSML 400
NIFTY SMALLCAP250 MOMENTUM QUALITY 100
NIFTY SMLCAP 250
NIFTY TOTAL MKT
NIFTY500 EQUAL WEIGHT
NIFTY500 LARGEMIDSMALL EQUAL CAP WEIGHTED
NIFTY500 MULTICAP
Eris Lifesciences Market Events Screener - Corporate Actions
Get Eris Lifesciences corporate actions including splits, bonuses, and buybacks.
Check Eris Lifesciences stock events that may affect ERIS share price.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| Annual General Meeting | NA | -9.82% | ||
| 2026-02-13 | 2026-02-13 | Quarterly Result Announcement | NA | 6.90% |
| 2025-11-12 | 2025-11-12 | Quarterly Result Announcement | NA | -0.28% |
| 2025-08-05 | 2025-08-05 | Quarterly Result Announcement | NA | 0.55% |
| 2025-07-25 | 2025-07-25 | Annual General Meeting | NA | 6.29% |
| 2025-05-19 | 2025-05-19 | Quarterly Result Announcement | NA | 4.50% |
| 2025-02-13 | 2025-02-13 | Dividend | ₹ 7.35 /share | -10.84% |
| 2025-02-04 | 2025-02-04 | Quarterly Result Announcement | NA | 7.93% |
| 2024-10-25 | 2024-10-25 | Quarterly Result Announcement | NA | -3.41% |
| 2022-08-11 | 2022-08-16 | Dividend | ₹ 7.35 /share | -0.23% |
| 2021-08-05 | 2021-08-06 | Dividend | ₹ 6.01 /share | 0.77% |
Eris Lifesciences Competitors Screener - Peer Comparison
Screen ERIS competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance for better
stock selection.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 406,351 | 37.86 | 54,729 | 9.71% | 10,980 | 37.98 |
| Divis Laboratories | 155,472 | 63.26 | 9,712 | 18.67% | 2,191 | 33.24 |
| Torrent Pharmaceuticals | 134,945 | 61.20 | 11,539 | 6.99% | 1,911 | 32.75 |
| Lupin | 103,954 | 22.26 | 22,910 | 13.74% | 3,306 | 47.35 |
| Dr Reddys Laboratories | 101,601 | 18.27 | 33,741 | 16.73% | 5,725 | 39.36 |
| Cipla | 96,320 | 21.31 | 28,410 | 7.12% | 5,291 | 26.86 |
| Zydus Life Science | 86,964 | 17.29 | 23,511 | 18.55% | 4,615 | 41.42 |
| Mankind Pharma | 82,499 | 45.81 | 12,744 | 20.90% | 2,007 | 41.40 |
| Aurobindo Pharma | 77,462 | 22.37 | 32,346 | 9.43% | 3,484 | 64.38 |
| Alkem Laboratories | 62,867 | 25.87 | 13,458 | 3.70% | 2,216 | 42.54 |
Eris Lifesciences Company Announcements - News Screener
Screen ERIS latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis.
| Date | Update | Actions |
|---|---|---|
| 2026-04-03 | Closure Of The Transaction Related To Acquisition Of Probiotics Business Of Velbiom Probiotics Private Limited. | - |
| 2026-03-30 | Closure of Trading Window | - |
| 2026-03-30 | Corporate Guarantee | - |
| 2026-03-20 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | - |
| 2026-03-20 | Board Meeting Outcome for The Meeting Held Today I.E. March 20 2026 | - |
| 2026-03-14 | Announcement under Regulation 30 (LODR)-Change in Directorate | - |
| 2026-03-13 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | - |
| 2026-03-12 | Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS | - |
| 2026-03-05 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | - |
| 2026-02-28 | Imposition Of Fine By BSE Limited And National Stock Exchange Of India Limited | - |
| 2026-02-24 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | - |
| 2026-02-23 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | - |
| 2026-02-20 | Corporate Presentation | - |
| 2026-02-20 | Announcement under Regulation 30 (LODR)-Earnings Call Transcript | - |
| 2026-02-19 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | - |
| 2026-02-13 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome | - |
| 2026-02-13 | Announcement under Regulation 30 (LODR)-Investor Presentation | - |
| 2026-02-13 | Unaudited Financial Results For The Quarter And Nine Months Ended December 31 2025 | - |
| 2026-02-13 | Board Meeting Outcome for Outcome Of Board Meeting | - |
| 2026-02-06 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | - |